Changes in Control of Registrant. At the Effective Time, pursuant to the terms of the Merger Agreement and the certificate of merger filed with the Secretary of State of the State of Delaware, the certificate of incorporation of the Company, as in effect immediately prior to the Effective Time, was amended and restated in its entirety. A copy of the amended and restated certificate of incorporation of the Company is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated h…

Material Modification to Rights of Security Holders. At the Effective Time, each share of Supernus Common Stock issued and outstanding immediately prior to the Effective Time (other than Excluded Shares, as defined in the Merger Agreement) was converted into the right to receive the Merger consideration described in

Entry into a Material Definitive Agreement. Credit Agreement On November 2, 2026 (the “ Closing Date ”), in connection with the Merger, the Combined Company and certain of its subsidiaries, including the Company (collectively, the “ Loan Parties ”), entered into a Credit Agreement (the “ Credit Agreement ”) by and among the Combined Company, as the borrower, the other Loan Parties, including the Company, as guarantors, the financial institutions from time to time party thereto as lenders, and…

Completion of Acquisition or Disposition of Assets. The disclosure in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. Subject to the terms and conditions of the Merger Agreement, at the Effective Time, and as a result of the Merger, each share of common stock of Supernus, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time (other than Excluded Shares, as defined in the Merger Agreement) was converted into the…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. In connection with the consummation of the Merger on November 2, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) notified Nasdaq of the completion of the Merger and requested that Nasdaq (i) suspend trading of the Supernus Common Stock, effective prior to the opening of trading on November 2, 2026, and (ii) file with the SEC a Notification of Removal from Listing and/or Registration on Fo…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Results of Operations and Financial Condition. On October 29, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Thursday, October 29, 2026, to present the business and financial r…

Termination of a Material Definitive Agreement. On October 20, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) terminated the UBS Credit Line Agreement, dated as of February 8, 2023 (the “UBS Credit Line”), between the Company and UBS Bank USA (the “Bank”), which established an uncommitted, demand revolving line of credit. The Company terminated the UBS Credit Line in anticipation of, and in connection with, the completion of the Company’s previously announced business combination with I…

Other Events. On October 21, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. The seven-year market exclusivity for ONAPGO began on February 3, 2025, the date of FDA approval. The Company also announced it submitted a supplemental Ne…

Results of Operations and Financial Condition. On October 19, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the third quarter of 2026 after the market closes on Thursday, October 29, 2026. The Company will host a conference call and webcast on Thursday, October 29, 2026 at 4:30 p.m. E.T. to discuss its third quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is…

The filing describes a new employment agreement for the current CEO and President, contingent on a merger.

Other Events. As previously announced, on August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) and Indivior Pharmaceuticals Inc. (“Indivior”) are hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger of the Company and Indivior. The Company intends to display the slides filed as Exhibit 99.1 hereto during the presentation. Important Additional Information and Where to Find It In connection with the proposed transaction…

Other Events. On August 3, 2026, the Company and Indivior issued a joint press release announcing the execution of the Merger Agreement. A copy of the joint press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. The Company and Indivior will host a joint conference call and webcast on Monday, August 3, 2026 at 8:30 a.m. EDT. A replay of the webcast will be available following the event. An investor presentation, which will be referenced during the webcast, will…

Results of Operations and Financial Condition On August 3, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus and Invidior Pharmaceuticals, Inc. ("Invidior") have entered into a definitive agreement to combine in an all-stock merger of equals…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On August 1, 2026 (the “Signing Date”), Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Supernus”), entered into a Merger Agreement (the “Merger Agreement”), by and among the Company, Indivior Pharmaceuticals Inc., a Delaware corporation (“Indivior”), and Artemis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Indivior (“Merger Sub”). Pursuant to the Merger Agreement, a…

Other Events. On August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc. (“Indivior”) on the Company’s LinkedIn account. In addition, on August 3, 2026, the Company distributed to its employees communications relating to the proposed merger, consisting of an email to Company employees from Jack A. Khattar, the Company’s President and Chief Executive Officer, and a presentation us…

Results of Operations and Financial Condition. On July 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the second quarter of 2026 after the market closes on Tuesday, August 4, 2026. The Company will host a conference call and webcast on Tuesday, August 4, 2026 at 4:30 p.m. E.T. to discuss its second quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorpo…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent, the Company notified the Rights Agent that Milestone 1, as d…

Results of Operations and Financial Condition. On May 5, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to present the business and financial results. A live…

Results of Operations and Financial Condition. On April 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the first quarter of 2026 after the market closes on Tuesday, May 5, 2026. The Company will host a conference call and webcast on Tuesday, May 5, 2026 at 4:30 p.m. E.T. to discuss its first quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated h…

Entry Into a Material Definitive Agreement. Entry into Asset Purchase Agreement On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”). The Agreement is entered into as co…

Completion of Acquisition or Disposition of Asset. The information set forth in

Compensation modifications and equity grants for executive officers.

Results of Operations and Financial Condition. On February 24, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, February 24, 2026, to present the business and financial…

Results of Operations and Financial Condition. On February 12, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter of 2025 after the market closes on Tuesday, February 24, 2026. The Company will host a conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. E.T. to discuss its fourth quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 heret…